Menu
Search
|

Menu

Close
X

ContraFect Corp CFRX.OQ (NASDAQ Stock Exchange Capital Market)

1.68 USD
-0.01 (-0.59%)
As of 7:13 PM GMT
chart
Previous Close 1.69
Open 1.74
Volume 7,389
3m Avg Volume 28,395
Today’s High 1.74
Today’s Low 1.65
52 Week High 2.45
52 Week Low 0.80
Shares Outstanding (mil) 73.66
Market Capitalization (mil) 95.02
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.245
FY16
-0.944
FY15
-1.081
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
4.85
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-104.45
14.43
Return on Equity (TTM)
vs sector
-153.83
16.13

EXECUTIVE LEADERSHIP

Steven Gilman
Chairman of the Board, Chief Executive Officer, Since 2017
Salary: --
Bonus: --
Joshua Muntner
Co-Chief Executive Officer, Senior Vice President - Business Development, Since 2017
Salary: --
Bonus: --
Michael Messinger
Co-Chief Executive Officer, Vice President - Finance, Since 2017
Salary: --
Bonus: --
Roger Pomerantz
Vice Chairman of the Board, Since 2014
Salary: --
Bonus: --
Nancy Dong
Vice President, Controller, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

28 Wells Ave Ste 3
YONKERS   NY   10701-7045

Phone: +1914.2072300

ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on discovering and developing therapeutic protein and antibody products for the treatment of infectious diseases, including those caused by drug-resistant pathogens, particularly those treated in hospital settings. Its pipeline of lysin candidates includes CF-301, CF-302, CF-303, CF-309, CF-304, CF-305, CF-306, CF-307 and CF-308. Its other product candidate includes CF-404. Its lysin product candidate, CF-301 is developed for the treatment of Staph aureus bacteremia, including endocarditis, caused by methicillin-resistant Staph aureus and susceptible Staph aureus strains. Its product candidate, CF-404 is used for the treatment of human influenza, including seasonal and pandemic varieties. It focuses on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses.

SPONSORED STORIES